SEPN - NASDAQ
Septerna, Inc.
$30.55
+2.0%Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotsepn
Selling, General and Administrative Expenses
Last Annual Value
29.16M
3-Year CAGR
70%
5-Year CAGR
38%
10-Year CAGR
17%
Septerna, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Septerna, Inc. NASDAQ:SEPN | 29.16M | 44.2% | N/A | N/A | |
 ProKidney Corp. NASDAQ:PROK | 51.78M | 4.9% | 42.4% | N/A | |
 Prime Medicine, Inc. NASDAQ:PRME | 52.35M | 6.5% | 30.3% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 51.70M | -0.1% | -0.5% | 19.1% | |
 Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX | 30.51M | 48.7% | N/A | N/A | |
 Tango Therapeutics, Inc. NASDAQ:TNGX | 41.51M | 5.3% | 18.7% | N/A | |
 Fortrea Holdings Inc. NASDAQ:FTRE | 456.40M | 0.6% | 8.5% | N/A | |
 Arbutus Biopharma Corporation NASDAQ:ABUS | 15.89M | -10.9% | -1.5% | -8.7% | |
 Nurix Therapeutics, Inc. NASDAQ:NRIX | 52.74M | 7.1% | 11.1% | N/A | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 171.47M | 4.2% | 11.4% | N/A | |
 Kura Oncology, Inc. NASDAQ:KURA | 119.98M | 33.4% | 20.9% | 31.2% |
Septerna, Inc. Fair Value Envelope
Related Guides
Continue your SEPN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.